Jason Gerberry
Stock Analyst at B of A Securities
(3.73)
# 768
Out of 5,044 analysts
162
Total ratings
57.76%
Success rate
5.13%
Average return
Main Sectors:
Stocks Rated by Jason Gerberry
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintains: Buy | $81 → $83 | $72.99 | +13.71% | 6 | Sep 23, 2025 | |
| AMPH Amphastar Pharmaceuticals | Maintains: Neutral | $28 → $32 | $24.04 | +33.11% | 2 | Aug 26, 2025 | |
| IMVT Immunovant | Maintains: Buy | $33 → $30 | $21.43 | +39.99% | 6 | Aug 12, 2025 | |
| BHVN Biohaven | Maintains: Buy | $50 → $49 | $17.39 | +181.77% | 2 | Aug 12, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $173 → $176 | $134.68 | +30.68% | 6 | Aug 5, 2025 | |
| PROK ProKidney | Downgrades: Underperform | $3 → $1 | $3.22 | -68.94% | 4 | Jun 30, 2025 | |
| LQDA Liquidia | Maintains: Buy | $25 → $23 | $22.76 | +1.05% | 2 | Jun 11, 2025 | |
| EXEL Exelixis | Maintains: Neutral | $45 → $46 | $39.99 | +15.03% | 3 | Jun 5, 2025 | |
| TEVA Teva Pharmaceutical Industries | Maintains: Buy | $20 → $22 | $19.61 | +12.19% | 14 | May 8, 2025 | |
| PCVX Vaxcyte | Maintains: Buy | $157 → $137 | $44.57 | +207.38% | 9 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $11 → $10 | $10.42 | -4.03% | 3 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $21.39 | +40.25% | 2 | Jan 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $84 → $100 | $86.70 | +15.34% | 5 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $24 | $7.38 | +225.20% | 1 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $20 | $21.56 | -7.21% | 3 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $41 → $31 | $31.00 | - | 6 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $600 → $550 | $6.03 | +9,021.06% | 3 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $27 → $29 | $29.72 | -2.42% | 9 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $29 → $37 | $39.48 | -6.28% | 2 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $52 → $56 | $41.89 | +33.68% | 2 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $30 | $30.11 | -0.37% | 2 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $204 → $217 | $139.33 | +55.75% | 5 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $100 → $50 | $10.94 | +357.04% | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $450 → $500 | $826.41 | -39.50% | 15 | May 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $9 | $1.23 | +631.71% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $37 → $25 | $7.06 | +254.11% | 3 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $45 → $5 | $1.87 | +167.38% | 2 | Dec 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $27 | $6.20 | +335.48% | 4 | Mar 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $20 | $1.60 | +1,150.00% | 1 | Jul 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $170 → $100 | $3.76 | +2,559.57% | 1 | Jul 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $95 | $228.03 | -58.34% | 10 | May 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $60 | $43.39 | +38.28% | 7 | Oct 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $37 | $24.77 | +49.37% | 4 | Oct 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $90 | $88.00 | +2.27% | 11 | Oct 17, 2019 |
Ionis Pharmaceuticals
Sep 23, 2025
Maintains: Buy
Price Target: $81 → $83
Current: $72.99
Upside: +13.71%
Amphastar Pharmaceuticals
Aug 26, 2025
Maintains: Neutral
Price Target: $28 → $32
Current: $24.04
Upside: +33.11%
Immunovant
Aug 12, 2025
Maintains: Buy
Price Target: $33 → $30
Current: $21.43
Upside: +39.99%
Biohaven
Aug 12, 2025
Maintains: Buy
Price Target: $50 → $49
Current: $17.39
Upside: +181.77%
Axsome Therapeutics
Aug 5, 2025
Maintains: Buy
Price Target: $173 → $176
Current: $134.68
Upside: +30.68%
ProKidney
Jun 30, 2025
Downgrades: Underperform
Price Target: $3 → $1
Current: $3.22
Upside: -68.94%
Liquidia
Jun 11, 2025
Maintains: Buy
Price Target: $25 → $23
Current: $22.76
Upside: +1.05%
Exelixis
Jun 5, 2025
Maintains: Neutral
Price Target: $45 → $46
Current: $39.99
Upside: +15.03%
Teva Pharmaceutical Industries
May 8, 2025
Maintains: Buy
Price Target: $20 → $22
Current: $19.61
Upside: +12.19%
Vaxcyte
Apr 1, 2025
Maintains: Buy
Price Target: $157 → $137
Current: $44.57
Upside: +207.38%
Feb 28, 2025
Maintains: Underperform
Price Target: $11 → $10
Current: $10.42
Upside: -4.03%
Jan 9, 2025
Reiterates: Buy
Price Target: $30
Current: $21.39
Upside: +40.25%
Nov 6, 2024
Maintains: Buy
Price Target: $84 → $100
Current: $86.70
Upside: +15.34%
Sep 10, 2024
Maintains: Buy
Price Target: $20 → $24
Current: $7.38
Upside: +225.20%
Jun 11, 2024
Maintains: Buy
Price Target: $21 → $20
Current: $21.56
Upside: -7.21%
Apr 1, 2024
Downgrades: Underperform
Price Target: $41 → $31
Current: $31.00
Upside: -
Mar 25, 2024
Maintains: Buy
Price Target: $600 → $550
Current: $6.03
Upside: +9,021.06%
Jan 2, 2024
Maintains: Neutral
Price Target: $27 → $29
Current: $29.72
Upside: -2.42%
Jan 2, 2024
Maintains: Buy
Price Target: $29 → $37
Current: $39.48
Upside: -6.28%
Jan 2, 2024
Maintains: Buy
Price Target: $52 → $56
Current: $41.89
Upside: +33.68%
Jan 2, 2024
Downgrades: Underperform
Price Target: $30
Current: $30.11
Upside: -0.37%
Aug 10, 2023
Maintains: Buy
Price Target: $204 → $217
Current: $139.33
Upside: +55.75%
Aug 8, 2023
Downgrades: Underperform
Price Target: $100 → $50
Current: $10.94
Upside: +357.04%
May 24, 2023
Maintains: Buy
Price Target: $450 → $500
Current: $826.41
Upside: -39.50%
Dec 12, 2022
Downgrades: Underperform
Price Target: $9
Current: $1.23
Upside: +631.71%
Oct 14, 2022
Downgrades: Underperform
Price Target: $37 → $25
Current: $7.06
Upside: +254.11%
Dec 2, 2021
Downgrades: Underperform
Price Target: $45 → $5
Current: $1.87
Upside: +167.38%
Mar 24, 2021
Downgrades: Underperform
Price Target: $27
Current: $6.20
Upside: +335.48%
Jul 16, 2020
Initiates: Neutral
Price Target: $20
Current: $1.60
Upside: +1,150.00%
Jul 15, 2020
Downgrades: Neutral
Price Target: $170 → $100
Current: $3.76
Upside: +2,559.57%
May 18, 2020
Reinstates: Neutral
Price Target: $95
Current: $228.03
Upside: -58.34%
Oct 17, 2019
Reinstates: Buy
Price Target: $60
Current: $43.39
Upside: +38.28%
Oct 17, 2019
Reinstates: Neutral
Price Target: $37
Current: $24.77
Upside: +49.37%
Oct 17, 2019
Reinstates: Neutral
Price Target: $90
Current: $88.00
Upside: +2.27%